Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive’s Hep C diagnostic device excels in African performance study

Africa is host to a wider variety of genomes than Europe, so Genedrive wanted to make sure its HCV ID Kit still worked well
genedrive hcv id kit
The test could tell, with 100% accuracy, whether or not a sample was infected with the virus

Genedrive PLC’s (LON:GDR) Hepatitis C (HCV) ID Kit has undergone more rigorous and successful testing – this time in Africa.

The handheld device which detects the virus was put through its paces by scientists at a testing laboratory in Johannesburg, South Africa.

READ: Handheld diagnostics specialist genedrive confirms award of £600,000 grant

AIM-listed Genedrive wanted to show that its HCV ID Kit would work just as well across the diverse genotypes which are prevalent in Africa compared to Europe.

In a cohort of 130 clinical samples from several sub-Saharan countries including South Africa, Kenya and Ghana, the device demonstrated sensitivity and specificity of 100%.

In layman’s terms, that means the HCV ID Kit correctly identified samples with the disease as well as correctly identifying those without.

On top of that, the scientists also found the device easy to operate which, compared to the Abbott M2000 platform, required no maintenance and had faster processing times.

"These positive results with the genedrive HCV assay in customer hands on local samples confirms that our good clinical validation performance can be translated into real-world settings where the test will be used,” said chief executive David Budd.

“We remain confident it can play an important role in the diagnosis and management of the disease in Africa and in other territories where access to centralized laboratories is limited.”

Towards the end of 2017, Genedrive signed a distribution agreement with Sysmex which will see the latter market and sell the HCV ID Kit and Genedrive platform in the EMEA region, with an initial focus on Africa.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use